GAP-f partners commit to:

Seek and direct funding to support the additional clinical research required to inform development and use of PADO priority products.

Action 17

Identify and facilitate the most suitable financial incentive for a given product included in PADO list, possibly including one or more of the following:

  • Support to development upon timely achievement of key milestones

  • Catalytic procurement

  • Advance market commitments.

Action 18

Seek and direct funding to support the additional clinical research required to inform development and use of PADO priority products.

Action 19

With the support of Unitaid, partner with Janssen and generic manufacturers to develop andregister DRV/r 120/20 mg by Q4 2020.

Pharmaceutical companies commit to:
Action 20

Manufacture new PADO priority pediatric ARV products “at risk” such that the new product isavailable for supply at time of approval/tentative approval/prequalification, including validation of manufacturing process during regulatory review.

Donors commit to:
Action 21

Support catalytic procurement of all or part of initial validation batches from manufacturers suchthat product availability is not delayed once approval or tentative approval is achieved.

Action 22

Incentivize commercialization of new pediatric ARV products “at risk” to accelerate introductionand scale up of new paediatric ARV product such that product is available at time ofapproval/tentative approval/prequalification.